Category

Cytomegalovirus (“CMV”)

VBI Vaccines Announces Poster Presentation at the 7th International Congenital CMV Conference & 17th International CMV Workshop

By | Conferences, Cytomegalovirus ("CMV"), Glioblastoma ("GBM"), Press Releases
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that David Anderson, Ph.D., Chief Scientific Officer, will present the poster, “CMV gB/pp65 eVLPs Formulated with GM-CSF as a Therapeutic Vaccine...
Read More

VBI Vaccines Announces Phase 2 Clinical Study Design of its Prophylactic CMV Vaccine Candidate

By | Cytomegalovirus ("CMV"), Press Releases
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced its plans for a Phase 2 clinical study evaluating VBI-1501, the company’s prophylactic cytomegalovirus (CMV) vaccine candidate, following positive discussions with Health...
Read More

VBI Vaccines Announces Formation of New Scientific and Clinical Advisory Boards

By | Cytomegalovirus ("CMV"), Glioblastoma ("GBM"), Press Releases, Sci-B-Vac®
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the formation of three Scientific and Clinical Advisory Boards (SABs) consisting of leading experts in infectious disease and immuno-oncology research and vaccine...
Read More